Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Mahamood Edavalath & Jeffrey W Stephens. (2010) Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives. Patient Preference and Adherence 4, pages 61-68.
Read now
Read now
Jason Seewoodhary, Leanne Griffin & Stephen C Bain. (2010) Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity 3, pages 165-172.
Read now
Read now
Lisa M Neff & Robert F Kushner. (2010) Emerging role of GLP-1 receptor agonists in the treatment of obesity. Diabetes, Metabolic Syndrome and Obesity 3, pages 263-273.
Read now
Read now
Carolyn F Deacon. (2009) Potential of liraglutide in the treatment of patients with type 2 diabetes. Vascular Health and Risk Management 5, pages 199-211.
Read now
Read now
Chee W Chia & Josephine M Egan. (2009) Role and development of GLP-1 receptor agonists in the management of diabetes. Diabetes, Metabolic Syndrome and Obesity 2, pages 37-49.
Read now
Read now
James Malone, Michael Trautmann, Ken Wilhelm, Kristin Taylor & David M Kendall. (2009) Exenatide once weekly for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs 18:3, pages 359-367.
Read now
Read now
Articles from other publishers (17)
Mingnan Cao, Chen Pan, Yue Tian, Li Wang, Zhigang Zhao & Bin Zhu. (2023) Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis. International Journal of Clinical Pharmacy 45:3, pages 689-697.
Crossref
Crossref
Fawzi Alogaili, Sivaprakasam Chinnarasu, Anja Jaeschke, Evangelia G. Kranias & David Y. Hui. (2020) Hepatic HAX-1 inactivation prevents metabolic diseases by enhancing mitochondrial activity and bile salt export. Journal of Biological Chemistry 295:14, pages 4631-4646.
Crossref
Crossref
Mark P. Plummer, Jeroen Hermanides & Adam M. Deane. (2019) Incretin Physiology and Pharmacology in the Intensive Care Unit. Critical Care Clinics 35:2, pages 341-355.
Crossref
Crossref
Sandra Ueberberg, Hendrik Jütte, Waldemar Uhl, Wolfgang Schmidt, Michael Nauck, Eduard Montanya, Andrea Tannapfel & Juris Meier. (2016) Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies. Diabetes, Obesity and Metabolism 18:12, pages 1253-1262.
Crossref
Crossref
Mark P Plummer, Marianne J Chapman, Michael Horowitz & Adam M Deane. (2014) Incretins and the intensivist: what are they and what does an intensivist need to know about them?. Critical Care 18:1, pages 205.
Crossref
Crossref
Samuel S. Engel, Elizabeth Round, Gregory T. Golm, Keith D. Kaufman & Barry J. Goldstein. (2013) Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies. Diabetes Therapy 4:1, pages 119-145.
Crossref
Crossref
Joshua J. Neumiller. (2011) Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment. Clinical Therapeutics 33:5, pages 528-576.
Crossref
Crossref
Jason Seewoodhary & Stephen C Bain. (2011) Novel treatments for type 2 diabetes. British Journal of General Practice 61:582, pages 5-6.
Crossref
Crossref
G. Schernthaner, A. H. Barnett, D. J. Betteridge, R. Carmena, A. Ceriello, B. Charbonnel, M. Hanefeld, R. Lehmann, M. T. Malecki, R. Nesto, V. Pirags, A. Scheen, J. Seufert, A. Sjohölm, A. Tsatsoulis & R. DeFronzo. (2010) Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 53:7, pages 1258-1269.
Crossref
Crossref
S. S. Engel, D. E. Williams-Herman, G. T. Golm, R. J. Clay, S. V. Machotka, K. D. Kaufman & B. J. Goldstein. (2010) Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. International Journal of Clinical Practice 64:7, pages 984-990.
Crossref
Crossref
M. Ligueros‐Saylan, J. E. Foley, A. Schweizer, A. Couturier & W. Kothny. (2010) An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes, Obesity and Metabolism 12:6, pages 495-509.
Crossref
Crossref
Brandi K Laliberte & Joshua J Neumiller. (2010) Review of Medications Used in the Treatment of Diabetes Mellitus. Journal of Pharmacy Technology 26:3, pages 136-146.
Crossref
Crossref
J. S. Nachnani, D. G. Bulchandani, A. Nookala, B. Herndon, A. Molteni, P. Pandya, R. Taylor, T. Quinn, L. Weide & L. M. Alba. (2009) Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 53:1, pages 153-159.
Crossref
Crossref
Jamie R. Robinson & Kevin D. Niswender. (2009) What are the risks and the benefits of current and emerging weight-loss medications?. Current Diabetes Reports 9:5, pages 368-375.
Crossref
Crossref
E. A. M. Gale. (2009) Collateral damage: the conundrum of drug safety. Diabetologia 52:10, pages 1975-1982.
Crossref
Crossref
Joshua J Neumiller & R Keith Campbell. (2009) Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus. Annals of Pharmacotherapy 43:9, pages 1433-1444.
Crossref
Crossref
DY Hui, MJ Cope, ED Labonté, H-T Chang, J Shao, E Goka, A Abousalham, D Charmot & J Buysse. (2009)
The phospholipase A
2
inhibitor methyl indoxam suppresses diet-induced obesity and glucose intolerance in mice
. British Journal of Pharmacology 157:7, pages 1263-1269.
Crossref
Crossref